

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 ( Not for submission under 37 CFR 1.99)

Application Number	10575779
Filing Date	2007-09-28
First Named Inventor	Michael Teifel
Art Unit	1633
Examiner Name	J. Shultz
Attorney Docket Number	062587-5007

**U.S.PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> <sup>4</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
			<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10575779
Filing Date	2007-09-28
First Named Inventor	Michael Teitel
Art Unit	1633
Examiner Name	J. Shultz
Attorney Docket Number	062587-5007

1	Sharma et al. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. <i>Cancer Research</i> 53: 5877-5881, 1993. <input type="checkbox"/>
2	Soepenberg et al. Real-time pharmacokinetics guiding clinical decisions: phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumors. <i>Eur. J. Cancer</i> 40: 681-688, 2004. <input type="checkbox"/>
3	Lohr et al. A phase II trial of cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer. <i>ESMO Poster Abstract</i> 6588, 2009. <input type="checkbox"/>
4	Australian Prescription Products Guide, 31st Edition, pages 3423-3426, 2002. <input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature /James Schultz/ (04/21/2011)

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.